FDAers on ‘corrupt’ list

Share this article:
Two FDA officials and an HHS official who slashed the FDA’s Warning Letter program by 70% early in the Bush administration are in the top four listings in Criminals and Scoundrels: The 25 Most Corrupt Officials of the Bush Administration issued by Citizens for Responsibility and Ethics in Washington (CREW).

Heading the alphabetical list is former HHS deputy secretary Claude A. Allen, who directed FDA chief counsel Daniel Troy to review all Warning Letters for legal sufficiency, a process that reduced their volume by 70%.

His CREW citation relates not to his HHS service but to his later arrest and conviction for shoplifting while later working at the White House.

The first FDA official listed is Commissioner’s Office official Margaret “Margo” Burnette, who is under investigation by the House Energy & Commerce Oversight and Investigations Committee for alleged conflicts of interest in awarding FDA contracts to Platinum Solutions, headed by her husband.

The second FDAer is former commissioner Lester M. Crawford, who was sentenced in February to three years’ supervised probation and fined $90,000 for lying about stock holdings in regulated companies that he and his wife maintained while he served as the top official at the agency. Crawford and his wife made roughly $39,000 from the illegally held stock.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.